Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evenamide in chronic schizophrenia
NCT04461119Phase 2Completed
- Sponsor
- Newron Pharmaceuticals
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of evenamide in schizophrenia (3 arms), sponsored by Newron Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at 4 weeks and Positive and Negative Syndrome Scale Total Score at 4 weeks. Started Jun 2020; status: completed.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04461119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04461119.